196 related articles for article (PubMed ID: 2543410)
1. A specific, photolabile and irreversible antagonist (L662,025) of the PAF-receptor.
Hussaini IM; Shen TY
Biochem Biophys Res Commun; 1989 May; 161(1):23-30. PubMed ID: 2543410
[TBL] [Abstract][Full Text] [Related]
2. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
[TBL] [Abstract][Full Text] [Related]
3. (+/-)-trans-2-(3-Methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5- trimethoxyphenyl)tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonist.
Ponpipom MM; Hwang SB; Doebber TW; Acton JJ; Alberts AW; Biftu T; Brooker DR; Bugianesi RL; Chabala JC; Gamble NL
Biochem Biophys Res Commun; 1988 Feb; 150(3):1213-20. PubMed ID: 2829894
[TBL] [Abstract][Full Text] [Related]
4. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: binding and in vitro functional studies.
Castro-Faria-Neto HC; Bozza PT; Cruz HN; Silva CL; Violante FA; Barbosa-Filho JM; Thomas G; Martins MA; Tibiriçá EV; Noel F
Planta Med; 1995 Apr; 61(2):101-5. PubMed ID: 7753913
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological evidence for the putative existence of two different subtypes of PAF receptors on platelets and leukocytes; studies with yangambin.
Herbert JM; Castro-Faria-Neto HC; Barbosa-Filho JM; Cordeiro RS; Tibiriça E
J Lipid Mediat Cell Signal; 1997 Sep; 17(1):1-14. PubMed ID: 9302650
[TBL] [Abstract][Full Text] [Related]
6. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
Herbert JM; Laplace MC; Maffrand JP
J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
[TBL] [Abstract][Full Text] [Related]
10. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
[TBL] [Abstract][Full Text] [Related]
11. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
Tahraoui L; Floch A; Cavero I
J Pharmacol Exp Ther; 1990 Mar; 252(3):1221-7. PubMed ID: 2156995
[TBL] [Abstract][Full Text] [Related]
12. Binding of [3H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes.
Herbert JM; Laplace MC; Maffrand JP
Biochem Pharmacol; 1993 Jan; 45(1):51-8. PubMed ID: 8381007
[TBL] [Abstract][Full Text] [Related]
13. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet.
Terashita Z; Imura Y; Nishikawa K
Biochem Pharmacol; 1985 May; 34(9):1491-5. PubMed ID: 2986648
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
15. L-659,989: a useful probe in the detection of multiple conformational states of PAF receptors.
Hwang SB; Lam MH
Lipids; 1991 Dec; 26(12):1148-53. PubMed ID: 1668109
[TBL] [Abstract][Full Text] [Related]
16. An antagonistic activity of etizolam on platelet-activating factor (PAF). In vitro effects on platelet aggregation and PAF receptor binding.
Mikashima H; Takehara S; Muramoto Y; Khomaru T; Terasawa M; Tahara T; Maruyama Y
Jpn J Pharmacol; 1987 Aug; 44(4):387-91. PubMed ID: 2890779
[TBL] [Abstract][Full Text] [Related]
17. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
Tahraoui L; Floch A; Mondot S; Cavero I
Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
[TBL] [Abstract][Full Text] [Related]
19. trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor.
Hwang SB; Lam MH; Biftu T; Beattie TR; Shen TY
J Biol Chem; 1985 Dec; 260(29):15639-45. PubMed ID: 2999126
[TBL] [Abstract][Full Text] [Related]
20. Competitive inhibition of tritium-labeled platelet-activating factor binding to rabbit platelet membranes by amiloride and amiloride analogs.
Hwang SB
Biochem Biophys Res Commun; 1989 Aug; 163(1):165-71. PubMed ID: 2549986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
